What You Should Know About Sinopharm, Its COVID-19 Vaccine and the Potential Impact of the WHO Approval May 13, 2021 | By Zixiang (George) Zhou, Associate, Bridge Consulting | Image source: China National Biotec Group On May 7, the World Health Organization officially listed the inactivated COVID-19 vaccine developed by the China National Biotec Group’s […]
November 12, 2020 | By Zixiang (George) Zhou, Associate, Bridge Consulting CEPI will fund Clover Biopharmaceuticals’ COVID-19 vaccine through a global Phase 2/3 clinical trial. Other Chinese COVID-19 vaccines continue to make progress, while yet other Chinese companies are developing COVID-19 vaccine global distribution solutions. Nonetheless, controversies over China’s COVID-19 vaccines remain. Although China has […]
Is China’s Vaccine Industry Ready to Contribute More to Global Health? At Beijing Bio-Institute Biological Products (BBIBP), the oldest vaccine development institute in China, millions of vials of vaccines are prepared for shipment. Partnership between BBIBP and PATH helps vaccines reach families in China and beyond. Source: PATH. October 1, 2020 | By Zixiang (George) […]
Can China Deliver on Its Promise to Make the COVID-19 Vaccine a Global Public Good? September 17, 2020 | By Zixiang (George) Zhou, Associate, Bridge Consulting| Chinese President Xi Jinping at the opening of the 73rd World Health Assembly, May 18, 2020. Source: Xinhua Need for International Cooperation on COVID-19 Vaccine R&D, Production, and Distribution […]